Published in PPAR Res on January 01, 2006
Postnatal weight and height growth velocities at different ages between birth and 5 y and body composition in adolescent boys and girls. Am J Clin Nutr (2008) 1.72
PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem (2009) 1.51
PPARG by dietary fat interaction influences bone mass in mice and humans. J Bone Miner Res (2008) 1.50
A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. Proc Natl Acad Sci U S A (2010) 1.46
Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology (2008) 1.26
TZDs and Bone: A Review of the Recent Clinical Evidence. PPAR Res (2008) 1.13
Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med (2009) 1.08
Skeletal aging and the adipocyte program: New insights from an "old" molecule. Cell Cycle (2010) 0.97
Plasma phosphatidylcholine concentrations of polyunsaturated fatty acids are differentially associated with hip bone mineral density and hip fracture in older adults: the Framingham Osteoporosis Study. J Bone Miner Res (2012) 0.86
Schnurri-3 is an essential regulator of osteoblast function and adult bone mass. Ann Rheum Dis (2007) 0.78
14-3-3γ Regulates Lipopolysaccharide-Induced Inflammatory Responses and Lactation in Dairy Cow Mammary Epithelial Cells by Inhibiting NF-κB and MAPKs and Up-Regulating mTOR Signaling. Int J Mol Sci (2015) 0.76
Effect of retinoic acid and vitamin D3 on osteoblast differentiation and activity in aging. J Bone Miner Metab (2015) 0.76
CD97/ADGRE5 Inhibits LPS Induced NF-κB Activation through PPAR-γ Upregulation in Macrophages. Mediators Inflamm (2016) 0.75
Mineralization content alters osteogenic responses of bone marrow stromal cells on hydroxyapatite/polycaprolactone composite nanofiber scaffolds. J Funct Biomater (2012) 0.75
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med (2002) 11.28
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells (2001) 6.86
Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature (2005) 6.43
Leptin regulates bone formation via the sympathetic nervous system. Cell (2002) 5.95
PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem (2001) 5.85
TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science (2005) 5.56
PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest (2004) 5.29
ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab (2002) 4.64
Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone (2003) 4.61
The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem (1997) 4.55
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A (2005) 4.48
Regulation of Wnt signaling during adipogenesis. J Biol Chem (2002) 3.94
Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci U S A (1995) 3.89
Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem (2005) 3.88
Wnt signaling in osteoblasts and bone diseases. Gene (2004) 3.72
Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell (2004) 3.55
High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res (2003) 3.48
Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem (1999) 3.18
Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem (2001) 3.17
PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev (2002) 3.17
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Playing with bone and fat. J Cell Biochem (2006) 2.94
Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology (2003) 2.84
Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology (2002) 2.50
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology (2004) 2.44
A new murine model of accelerated senescence. Mech Ageing Dev (1981) 2.40
Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest (1996) 2.26
Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone (2003) 2.17
Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science (2004) 2.15
Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J (2004) 2.12
The function of adipocytes in the bone marrow stroma: an update. Bone (1996) 2.01
Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl (1996) 1.96
Adiponectin and its receptors are expressed in bone-forming cells. Bone (2004) 1.86
alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev (2005) 1.81
Regulation of osteoblast formation and function. Rev Endocr Metab Disord (2001) 1.80
Red and yellow marrow in the femur: age-related changes in appearance at MR imaging. Radiology (1990) 1.79
TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle (2006) 1.76
Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int (2004) 1.69
Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol (2003) 1.69
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol (2004) 1.67
Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res (2005) 1.64
Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone (2004) 1.53
Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res (1997) 1.49
A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem (1998) 1.48
Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem (2006) 1.46
LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res (2004) 1.45
PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett (1998) 1.38
Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep (2004) 1.37
Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology (2006) 1.36
Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res (2003) 1.33
Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int (2001) 1.32
Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun (1999) 1.31
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone (2005) 1.28
IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci U S A (2001) 1.26
Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res (2005) 1.22
Influence of mature adipocytes on osteoblast proliferation in human primary cocultures. Bone (2000) 1.20
Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest (2002) 1.19
Paracrine regulation of osteoclast formation and activity: milestones in discovery. J Musculoskelet Neuronal Interact (2004) 1.16
Transforming growth factor beta2 inhibits adipocyte differentiation induced by skeletal unloading in rat bone marrow stroma. J Bone Miner Res (2002) 1.15
A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol (2003) 1.12
Leptin, bone mass, and the thrifty phenotype. J Bone Miner Res (2004) 1.11
DeltaFosB induces osteosclerosis and decreases adipogenesis by two independent cell-autonomous mechanisms. Mol Cell Biol (2004) 1.07
Insulin-like growth factor I and bone mineral density: experience from animal models and human observational studies. Best Pract Res Clin Endocrinol Metab (2004) 1.05
Inhibition of osteoblast differentiation but not adipocyte differentiation of mesenchymal stem cells by sera obtained from aged females. Bone (2006) 1.03
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology (1999) 1.02
Marrow changes in paraplegic patients. Calcif Tissue Int (1984) 1.02
B cells and osteoblast and osteoclast development. Immunol Rev (2005) 1.02
Human ALOX12, but not ALOX15, is associated with BMD in white men and women. J Bone Miner Res (2006) 1.00
Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J (1999) 0.97
Role of polyunsaturated fatty acids in the inhibitory effect of human adipocytes on osteoblastic proliferation. Bone (2002) 0.96
Mice deficient in 11beta-hydroxysteroid dehydrogenase type 1 lack bone marrow adipocytes, but maintain normal bone formation. Endocrinology (2004) 0.94
Treatment of senile osteoporosis in SAMP6 mice by intra-bone marrow injection of allogeneic bone marrow cells. Stem Cells (2005) 0.93
Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones. Endocrinology (2005) 0.93
Skeletal changes during space flight. Lancet (1985) 0.92
Growth hormone (GH) status and body composition in normal ageing and in elderly adults with GH deficiency. Horm Res (2003) 0.92
Regulation of bone mass by mechanical loading: microarchitecture and genetics. Curr Osteoporos Rep (2005) 0.92
The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol (2005) 0.88
Radiological features in generalized lipodystrophy. Acta Paediatr Suppl (1996) 0.87
PPAR Gamma Activity and Control of Bone Mass in Skeletal Unloading. PPAR Res (2006) 0.86
Impaired marrow osteogenesis is associated with reduced endocortical bone formation but does not impair periosteal bone formation in long bones of SAMP6 mice. J Bone Miner Res (2004) 0.85
Association of a single nucleotide polymorphism in the lipoxygenase ALOX15 5'-flanking region (-5229G/A) with bone mineral density. J Bone Miner Metab (2005) 0.85
Mice lacking 5-lipoxygenase have increased cortical bone thickness. Adv Exp Med Biol (1997) 0.82
Genetic strategies for elucidating insulin-like growth factor action in bone. Growth Horm IGF Res (2004) 0.82
Skeletal unloading induces biphasic changes in insulin-like growth factor-I mRNA levels and osteoblast activity. Exp Cell Res (1999) 0.79
Insulin-like growth factor I and calcium balance: evolving concepts of an evolutionary process. Endocrinology (2003) 0.78
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A (2005) 4.48
Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology (2007) 2.22
Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab (2006) 2.04
Indian Hedgehog produced by postnatal chondrocytes is essential for maintaining a growth plate and trabecular bone. Proc Natl Acad Sci U S A (2007) 1.85
Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J Theor Biol (2004) 1.77
Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. Matrix Biol (2004) 1.75
Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone (2003) 1.66
Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res (2005) 1.65
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One (2008) 1.60
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood (2007) 1.49
Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res (2002) 1.46
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol (2006) 1.44
Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology (2006) 1.41
Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood (2004) 1.38
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res (2013) 1.29
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone (2005) 1.28
Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res (2010) 1.18
Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res (2005) 1.16
Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res (2011) 1.11
Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia (2004) 1.08
Aging alters the skeletal response to disuse in the rat. Am J Physiol Regul Integr Comp Physiol (2006) 1.06
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica (2012) 1.05
Breast cancer metastasis to bone: it is not all about PTHrP. Clin Orthop Relat Res (2003) 1.02
Bone turnover across the menopause transition : The role of gonadal inhibins. Ann N Y Acad Sci (2010) 1.02
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res (2008) 1.00
The somatotrope as a metabolic sensor: deletion of leptin receptors causes obesity. Endocrinology (2010) 0.99
Early detection of bone infection and differentiation from post-surgical inflammation using 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography (FDG-PET) in an animal model. J Orthop Res (2005) 0.97
Rapid loss of bone mass and strength in mice after abdominal irradiation. Radiat Res (2011) 0.96
Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone (2008) 0.94
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica (2010) 0.94
Relationship of bicipital groove rotation with humeral head retroversion: a three-dimensional computed tomographic analysis. J Bone Joint Surg Am (2013) 0.93
Interleukin-1 and tumor necrosis factor antagonists attenuate ethanol-induced inhibition of bone formation in a rat model of distraction osteogenesis. J Pharmacol Exp Ther (2002) 0.93
Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin. Mol Cell Endocrinol (2009) 0.93
Investigation of the regulation of bone mass by mechanical loading: from quantitative cytochemistry to gene array. Cell Biochem Funct (2003) 0.91
Ethanol-induced inhibition of bone formation in a rat model of distraction osteogenesis: a role for the tumor necrosis factor signaling axis. Alcohol Clin Exp Res (2005) 0.89
Skeletal toxicity associated with chronic ethanol exposure in a rat model using total enteral nutrition. J Pharmacol Exp Ther (2002) 0.89
Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation. Calcif Tissue Int (2012) 0.87
Vitamin D supplementation protects against bone loss associated with chronic alcohol administration in female mice. J Pharmacol Exp Ther (2012) 0.87
Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasis. Cancer Epidemiol Biomarkers Prev (2013) 0.87
Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. J Cell Biochem (2008) 0.86
Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women. J Bone Miner Res (2008) 0.86
Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment. PLoS One (2012) 0.86
Comparison of biomechanical properties of alloderm and enduragen as static facial sling biomaterials. Laryngoscope (2006) 0.85
Concurrent septic arthritis and osteomyelitis in children. J Pediatr Orthop (2013) 0.85
Two-incision versus one-incision repair for distal biceps tendon rupture: a cadaveric study. J Shoulder Elbow Surg (2011) 0.84
Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. J Bone Miner Res (2010) 0.84
Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone (2013) 0.83
The promise of bone cancer proteomics. Ann N Y Acad Sci (2010) 0.83
Genomics and proteomics of bone cancer. Clin Cancer Res (2006) 0.82
Proteomic analysis of bone cancer: a review of current and future developments. Expert Rev Proteomics (2007) 0.82
Inhibin A enhances bone formation during distraction osteogenesis. J Orthop Res (2011) 0.82
Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics. Bone (2005) 0.82
Characterization of the glycosylation profile of the human breast cancer cell line, MDA-231, and a bone colonizing variant. Int J Oncol (2006) 0.81
Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark (2006) 0.81
Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. J Bone Miner Res (2011) 0.81
Cisplatin inhibits bone healing during distraction osteogenesis. J Orthop Res (2013) 0.81
Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent. Radiat Res (2010) 0.80
Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. Br J Haematol (2009) 0.80
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res (2006) 0.80
Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools. Dis Markers (2006) 0.80
TASR-1 regulates alternative splicing of collagen genes in chondrogenic cells. Biochem Biophys Res Commun (2007) 0.79
Loss of functional NADPH oxidase 2 protects against alcohol-induced bone resorption in female p47phox-/- mice. Alcohol Clin Exp Res (2013) 0.79
Sc65 is a novel endoplasmic reticulum protein that regulates bone mass homeostasis. J Bone Miner Res (2014) 0.78
Oral glutamine reduces radiation morbidity in breast conservation surgery. JPEN J Parenter Enteral Nutr (2013) 0.77
Hormonal causes of menopausal bone resorption. Curr Osteoporos Rep (2011) 0.75
Imaging bone blood perfusion: not just going with the flow. Bone (2013) 0.75
PTH expression, not always where you think ... J Clin Endocrinol Metab (2006) 0.75
Aneuploidy and skeletal health. Curr Osteoporos Rep (2014) 0.75
Proteomic technologies for the study of osteosarcoma. Sarcoma (2012) 0.75
Platelets to hemostasis and beyond. Blood (2011) 0.75
Treatment of subperiosteal abscesses in children: is drainage of the intramedullary canal required? J Pediatr Orthop B (2016) 0.75
Microcomputed tomography assessment of glenoid component cementation techniques in total shoulder arthroplasty. J Orthop Res (2010) 0.75
Presentation and Management of Venomous Snakebites: Should All Patients Be Transferred to a Tertiary Referral Hospital? J Surg Orthop Adv (2016) 0.75